Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.
Bezençon O, Siegrist R, Heidmann B, Pozzi D, Stamm S, Remeň L, Richard S, Simons L, Gaston R, Downing D, Grisostomi C, Roch C, Kessler M, Gatfield J, Moon R, Pfeifer T, Mosbacher J, Reymond I, Ertel EA, de Kanter R, Capeleto B, Fournier E, Rey M, Moccia L, Toeroek-Schafroth M, Roscher R, Schindelholz B. Bezençon O, et al. Chimia (Aarau). 2017 Oct 25;71(10):722-729. doi: 10.2533/chimia.2017.722. Chimia (Aarau). 2017. PMID: 29070417 Free article.
Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.
Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Moon R, Corminboeuf O, Bezençon O. Siegrist R, et al. Among authors: bezencon o. J Med Chem. 2016 Dec 8;59(23):10661-10675. doi: 10.1021/acs.jmedchem.6b01356. Epub 2016 Nov 23. J Med Chem. 2016. PMID: 27933950
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.
Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E. Bezençon O, et al. J Med Chem. 2017 Dec 14;60(23):9769-9789. doi: 10.1021/acs.jmedchem.7b01236. Epub 2017 Nov 20. J Med Chem. 2017. PMID: 29116786
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Bezençon O, Bur D, Weller T, Richard-Bildstein S, Remen L, Sifferlen T, Corminboeuf O, Grisostomi C, Boss C, Prade L, Delahaye S, Treiber A, Strickner P, Binkert C, Hess P, Steiner B, Fischli W. Bezençon O, et al. J Med Chem. 2009 Jun 25;52(12):3689-702. doi: 10.1021/jm900022f. J Med Chem. 2009. PMID: 19358611
Design and optimization of new piperidines as renin inhibitors.
Corminboeuf O, Bezençon O, Grisostomi C, Remeň L, Richard-Bildstein S, Bur D, Prade L, Hess P, Strickner P, Fischli W, Steiner B, Treiber A. Corminboeuf O, et al. Among authors: bezencon o. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6286-90. doi: 10.1016/j.bmcl.2010.08.086. Epub 2010 Aug 22. Bioorg Med Chem Lett. 2010. PMID: 20843686
Correction to Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.
Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Moon R, Corminboeuf O, Bezençon O. Siegrist R, et al. Among authors: bezencon o. J Med Chem. 2017 Mar 9;60(5):2163. doi: 10.1021/acs.jmedchem.7b00219. Epub 2017 Feb 24. J Med Chem. 2017. PMID: 28234473 No abstract available.
Piperidine-based renin inhibitors: upper chain optimization.
Corminboeuf O, Bezençon O, Remeň L, Grisostomi C, Richard-Bildstein S, Bur D, Prade L, Strickner P, Hess P, Fischli W, Steiner B, Treiber A. Corminboeuf O, et al. Among authors: bezencon o. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6291-6. doi: 10.1016/j.bmcl.2010.08.087. Epub 2010 Aug 22. Bioorg Med Chem Lett. 2010. PMID: 20843690
12 results